KPRX · Insider Trading
Kiora Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by KPRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Keith J. Lane | — | A | +55,000 deriv. | — |
| 2026-07-02 | Melissa Tosca | CFO | F | −911 | −$2.42K |
| 2026-07-02 | Brian M. Strem | President and CEO | F | −1,869 | −$4.97K |
| 2026-06-12 | Aron Shapiro | Director | A | +25,000 deriv. | — |
| 2026-06-12 | Erin Parsons | Director | A | +25,000 deriv. | — |
| 2026-06-12 | Carmine N. Stengone | Director | A | +25,000 deriv. | — |
| 2026-06-12 | Praveen Tyle | Director | A | +40,000 deriv. | — |
| 2026-06-12 | David Hollander | Director | A | +25,000 deriv. | — |
| 2026-06-12 | Lisa Walters-Hoffert | Director | A | +25,000 deriv. | — |
| 2026-04-02 | Eric Joseph Daniels | Chief Development Officer | F | −929 | −$1.81K |
| 2026-04-02 | Brian M. Strem | President and CEO | F | −1,906 | −$3.72K |
| 2026-04-02 | Melissa Tosca | CFO | F | −929 | −$1.81K |
| 2026-03-10 | Brian M. Strem | President and CEO | A | +16,733 | — |
| 2026-03-10 | Melissa Tosca | CFO | A | +6,533 | — |
| 2026-03-10 | Eric Joseph Daniels | Chief Development Officer | A | +6,533 | — |
| 2026-03-06 | Brian M. Strem | President and CEO | F | −238 | −$481 |
| 2026-03-06 | Eric Joseph Daniels | Chief Development Officer | F | −238 | −$481 |
| 2025-04-02 | Praveen Tyle | Director | A | +30,000 deriv. | — |
| 2025-04-02 | Aron Shapiro | Director | A | +20,000 deriv. | — |
| 2025-04-02 | Lisa Walters-Hoffert | Director | A | +20,000 deriv. | — |
| 2025-04-02 | David Hollander | Director | A | +20,000 deriv. | — |
| 2025-04-02 | Eric Joseph Daniels | Chief Development Officer | A | +7,772 | — |
| 2025-04-02 | Carmine N. Stengone | Director | A | +20,000 deriv. | — |
| 2025-04-02 | Brian M. Strem | President and CEO | A | +15,941 | — |
| 2025-04-02 | Erin Parsons | Director | A | +20,000 deriv. | — |
| 2025-04-02 | Melissa Tosca | CFO | A | +7,772 | — |
| 2024-09-12 | Carmine N. Stengone | Director | Buy | +1,250 | +$4.60K |
| 2024-09-11 | Aron Shapiro | Director | Buy | +3,000 | +$10.80K |
| 2024-08-20 | Lisa Walters-Hoffert | Director | Buy | +1,250 | +$4.83K |
| 2024-08-19 | Praveen Tyle | Director | Buy | +5,000 | +$19.80K |
| 2024-08-15 | Melissa Tosca | CFO | Buy | +2,000 | +$6.42K |
| 2024-07-03 | Lisa Walters-Hoffert | Director | A | +1,778 deriv. | — |
| 2024-07-03 | Carmine N. Stengone | Director | A | +1,778 deriv. | — |
| 2024-07-03 | David Hollander | Director | A | +1,778 deriv. | — |
| 2024-07-03 | Brian M. Strem | President and CEO | A | +15,629 | — |
| 2024-07-03 | Aron Shapiro | Director | A | +1,778 deriv. | — |
| 2024-07-03 | Erin Parsons | Director | A | +1,778 deriv. | — |
| 2024-07-03 | Eric Joseph Daniels | Chief Development Officer | A | +7,355 | — |
| 2024-07-03 | Praveen Tyle | Director | A | +1,778 deriv. | — |
| 2024-07-03 | Melissa Tosca | CFO | A | +7,620 | — |
| 2024-06-14 | Melissa Tosca | EVP Finance | Buy | +100 | +$525 |
| 2024-06-14 | Eric Joseph Daniels | Chief Development Officer | Buy | +1,431 | +$7.57K |
| 2024-06-13 | Erin Parsons | Director | Buy | +5,260 | +$25.67K |
| 2024-06-13 | Brian M. Strem | President and CEO | Buy | +3,000 | +$15.00K |
| 2023-10-03 | Eric Joseph Daniels | Chief Development Officer | A | +62,500 | — |
| 2023-10-03 | Erin Parsons | Director | A | +5,000 deriv. | — |
| 2023-10-03 | Aron Shapiro | Director | A | +5,000 deriv. | — |
| 2023-10-03 | Kenneth L Gayron | Director | A | +5,000 deriv. | — |
| 2023-10-03 | David Hollander | Director | A | — | — |
| 2023-10-03 | Melissa Tosca | EVP Finance | A | +30,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Brian M. Strem | President and CEO | 58,823 | $130.00K |
| Eric Joseph Daniels | Chief Development Officer | 31,741 | $70.15K |
| Melissa Tosca | CFO | 26,064 | $57.60K |
| Erin Parsons | Director | 5,260 | $11.62K |
| Praveen Tyle | Director | 5,014 | $11.08K |
| Aron Shapiro | Director | 3,000 | $6.63K |
| Lisa Walters-Hoffert | Director | 1,250 | $2.76K |
| Carmine N. Stengone | Director | 1,250 | $2.76K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KPRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.